Itzhak Perlman Headlines Great Neck Park District’s Summer Concert Series
1 day ago
United States David Baker is a Nobel laureate and a leading figure in computational biology, renowned for pioneering methods to design proteins and predict their three-dimensional structures.
Co-founded by Nobel Laureate David Baker, Arzeda drives industry innovation with Intelligent Protein Design Technology™ and delivers advanced solutions.
David Baker's 2024 Nobel Prize-winning work is being used in collaboration with Julia Mahamid to design new self-assembling protein labels for electron microscopy.
Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed funding, focusing on protein design and antibody cages.
Baker is credited as a founder, co-founder, or scientific co-founder of 21 biotech companies, including AI drug discovery company Charm.
Hear 2024 Nobel Prize laureates David Baker and Victor Ambros speak about the importance of collaboration in science.
Baker also set up a biochemistry lab to study amino acid interactions, in order to improve his models. Early on, Baker and Kim Simons, one of his first graduate students, set about improving protein prediction software.
Nobel laureate David Baker's discussion on AI's impact on life science and healthcare startups, highlighting his groundbreaking research in protein structures and numerous awards.
Co-founded by Baker, Prospect Genomics was acquired by an Eli Lilly subsidiary in 2001.
Co-founded by Baker, Icosavax was acquired by AstraZeneca in 2023.
Baker is a co-founder of Sana Biotechnology.
Baker is a co-founder of Lyell Immunotherapeutics.
Baker is a co-founder of Xaira Therapeutics.
David Baker, born in Seattle, Washington, in 1962, is an American biochemist and computational biologist. He pursued a Bachelor of Arts in biology from Harvard University in 1984. He then earned his Ph.D. in biochemistry from the University of California, Berkeley, in 1989, where his research focused on protein transport in yeast systems. Following his doctoral studies, Baker completed postdoctoral research in structural biology at the University of California, San Francisco, shifting his focus to protein folding. His early academic journey laid the foundation for his later groundbreaking contributions to protein design and prediction.
In 1993, Baker joined the faculty at the University of Washington, where he embarked on in-depth investigations into protein folding and how amino acid sequences determine protein shapes. This work led to the development of Rosetta, a computational platform for predicting and designing protein structures. Rosetta, utilizing a Monte Carlo sampling algorithm, was successfully applied in the Critical Assessment of Protein Structure Prediction (CASP) competition, demonstrating its accuracy in predicting protein folds from amino acid sequences. His team later reversed this process to design proteins with specific shapes, culminating in 2003 with the creation of Top7, the first de novo designed protein. Baker made Rosetta’s code publicly available, fostering widespread innovation in protein engineering.
Baker’s contributions have significantly advanced synthetic biology and the development of new drugs and industrial proteins. He has designed mini-proteins for therapeutic uses, such as inhibiting the SARS-CoV-2 virus. His work has earned him numerous accolades, including the 2024 Nobel Prize in Chemistry for breakthroughs in computational protein design. He is also a Howard Hughes Medical Institute Investigator and a member of the National Academy of Sciences. Beyond his academic work, Baker has co-founded 21 biotechnology companies, driving the translation of his research into practical applications across various sectors.
Curious about our offerings or have inquiries? We're eager to assist!
Just complete the form, and we'll respond promptly.
